A Phase 3 interventional study of Core Treatment Active Experimental: SHR0302 Dose#1 and Core Treatment Active Experimental: SHR0302 Dose#2 in Atopic Dermatitis, sponsored by Reistone Biopharma Company Limited. Completed at 52 sites in 2 countries. Open to participants aged 12 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-06-01.
Sponsored by Reistone Biopharma Company Limited (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Dermatitis, Atopic by Jiangsu HengRui Medicine Co., Ltd. — 3 open to participants now, 5 under way, 2 of them phase 3. Dermatitis, Atopic · Jiangsu HengRui Medicine Co., Ltd..
Among the 14 studies in Dermatitis, Atopic by Jiangsu HengRui Medicine Co., Ltd., this one is the 3rd largest by enrollment, is the only one that started in 2021, is one of 3 in phase 3, and was the 3rd registered.
1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.
Browse Dermatitis, Atopic studies →3 of the 14 studies in Dermatitis, Atopic by Jiangsu HengRui Medicine Co., Ltd. are open now, in 1 country. Recruiting first, the newest first:
Guangdong Hengrui Pharmaceutical Co., Ltd · Sites in China
Ages 12–17
Guangdong Hengrui Pharmaceutical Co., Ltd · Sites in China
Ages 18–75
Chengdu Suncadia Medicine Co., Ltd. · Sites in China
Ages 18–55 · Healthy volunteers
By country, each count listing its studies:
Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.
This study: 12 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 8 · Phase 3 4
First in 2019; this study’s year is marked. 1 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 336 is above the median of 82 across 1,248 interventional studies indexed under Dermatitis, Atopic.
Median enrollment 159 across the 14 interventional studies. Of the 9 that completed or were terminated, 1 (11%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Reistone Biopharma Company Limited, one of the names counted as Jiangsu HengRui Medicine Co., Ltd.. Under that name alone:
Reistone Biopharma Company Limited is the lead sponsor of 16 studies on the registry; 4 are open to participants now.
3 of the studies in Dermatitis, Atopic by Jiangsu HengRui Medicine Co., Ltd. that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07309055Phase 3Guangdong Hengrui Pharmaceutical Co., LtdA Study of SHR-1819 Injection in Adolescents With Severe Atopic Dermatitis | 2027-11 |
| NCT07698756Chengdu Suncadia Medicine Co., Ltd.A Clinical Study of HRS-8797 in Healthy Participants | 2026-12 |
| NCT07321951Guangdong Hengrui Pharmaceutical Co., LtdA Study of SHR-1819 in Patients With Moderate-to-severe Atopic Dermatitis | 2027-06 |
Add all 3 to your calendar (.ics) → With an account.
Among the 14 studies in Dermatitis, Atopic by Jiangsu HengRui Medicine Co., Ltd., from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a randomized, double-blind, placebo-controlled, multicenter Phase 3 study that will enroll approximately 330 subjects aged 12 to 75 years old with moderate to severe atopic dermatitis.
This study consists of a screening period followed by a placebo-controlled treatment period and then an extension treatment period and completed after a follow-up period after the completion of active treatment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: SHR0302 Oral tablets taken once daily (QD) for 16 weeks
Drug: Core Treatment Active Experimental: SHR0302 Dose#1
Drug: SHR0302 Oral tablets taken once daily (QD) for 16 weeks
Drug: Core Treatment Active Experimental: SHR0302 Dose#2
Drug: Placebo Oral tablets taken once daily (QD) for 16 weeks
Drug: Core Treatment Placebo Comparator: Placebo
Drug: SHR0302 Oral tablets taken once daily (QD) for 36 weeks
Drug: Extension Treatment Active Experimental: SHR0302 Dose#1
Drug: SHR0302 Oral tablets taken once daily (QD) for 36 weeks
Drug: Extension Treatment Active Experimental: SHR0302 Dose#2
Drug: SHR0302 Oral tablets taken once daily (QD) for 16 weeks
Drug: SHR0302 Oral tablets taken once daily (QD) for 16 weeks
Drug: Placebo Oral tablets taken once daily (QD) for 16 weeks
Drug: SHR0302 Oral tablets taken once daily (QD) for 36 weeks
Drug: SHR0302 Oral tablets taken once daily (QD) for 36 weeks
Investigator's Global Assessment (IGA) score of 0/1 at Week 16
Proportion of subjects achieving Investigator's Global Assessment (IGA) score of clear (0) or almost clear (1) and a reduction from baseline of ≥2 points at Week 16.
Time frame: 16 Weeks
Eczema Area and Severity Index (EASI 75) at Week 16
Proportion of subjects achieving at least a 75% improvement in Eczema Area and Severity Index (EASI 75) from baseline at Week 16.
Time frame: 16 Weeks
Worst-Itch Numeric Rating Scale (WI-NRS-4)-4 at Week 16
Proportion of subjects achieving an improvement of Worst-Itch Numeric Rating Scale (WI-NRS) ≥4 from baseline at Week 16
Time frame: Week 16
Worst-Itch Numeric Rating Scale (WI-NRS) at Week 1, 4, 8 and 12
Proportion of subjects achieving an improvement of WI-NRS ≥4 from baseline at all scheduled visits during placebo-controlled treatment phase other than Week 16.
Time frame: Week 1, 4, 8 and 12
Time to WI-NRS response
Time from baseline to achieve at least 4 points improvement of WI-NRS during placebo-controlled treatment phase.
Time frame: Baseline to Week 16
EASI 75 at Week 1, 4, 8 and 12
Proportion of subjects achieving EASI 75 at all scheduled visits during placebo-controlled treatment phase except Week 16.
Time frame: Week 1, 4, 8 and 12
IGA 0/1 at Week 1, 4, 8 and 12
Proportion of subjects achieving IGA0/1 and a reduction from baseline of ≥2 points at all scheduled visits during placebo-controlled treatment phase except Week 16.
Time frame: Week 1, 4, 8 and 12
NRS-4 at Week 24, 32, 40, 52 and 56
Proportion of subjects achieving an improvement of WI-NRS ≥4 from baseline at all scheduled visits during extension treatment phase.
Time frame: All scheduled visits from Week 24 - 56
EASI 75 at Week 24, 32, 40, 52 and 56
Proportion of subjects achieving EASI 75 at all scheduled visits during extension treatment phase.
Time frame: All scheduled visits from Week 16 24 - 56
IGA 0/1 at Week 24, 32, 40, 52 and 56
Proportion of subjects achieving IGA0/1 and a reduction from baseline of ≥2 points at all scheduled visits during extension treatment phase.
Time frame: All scheduled visits from Week 24 - 56
EASI 50 and EASI 90 at Week 1, 4, 8, 12, 16, 24, 32, 40, 52 and 56
Proportion of subjects with ≥50% EASI improvement from baseline (EASI 50) at all scheduled visits.
Time frame: Day 1 to Week 56
Change of EASI from baseline at Week 1, 4, 8, 12, 16, 24, 32, 40, 52 and 56
Change from baseline in the eczema area and severity index (EASI) total score at all scheduled visits. The EASI score ranges from 0.0 to 72.0, can be varied in increments of 0.1, Higher scores indicate greater severity.
Time frame: Day 1 to Week 56
SCORAD 50, SCORAD 75 and SCORAD 90 at Week 1, 4, 8, 12, 16, 24, 32, 40, 52 and 56
SCORing Atopic Dermatitis (SCORAD). Score of 0-103. Higher scores mean more severe. Proportion of subjects achieving a ≥50%, 75% and 90% improvement in SCORAD (SCORAD 50, SCORAD 75 and SCORAD 90) from baseline at all scheduled visits.
Time frame: Day 1 to Week 56
Change of SCORAD from baseline at Week 1, 4, 8, 12, 16, 24, 32, 40, 52 and 56
Change from baseline in SCORAD at all scheduled visits
Time frame: Day 1 to Week 56
Change of BSA from baseline at Week 1, 4, 8, 12, 16, 24, 32, 40, 52 and 56
Change from baseline in body surface area (BSA) affected at all scheduled visits
Time frame: Day 1 to Week 56
Change of IgE from baseline at Week 1, 4, 8, 12, 16, 24, 32, 40, 52 and 56
Change from baseline in the level of serum IgE in peripheral blood at all scheduled visits.
Time frame: Day 1 to Week 56
Change of eosinophils from baseline at Week 1, 4, 8, 12, 16, 24, 32, 40, 52 and 56
Change from baseline in the level of serum eosinophils in peripheral blood at all scheduled visits.
Time frame: Day 1 to Week 56
Change of dermatology life quality index (DLQI) or Children's DLQI (CDLQI) PROs from baseline at Week 4, 8, 12, 16, 24, 32, 40, 52 and 56
Change from baseline in dermatology life quality index (DLQI) or Children's DLQI (CDLQI) score at all scheduled visits. The DLQI CDLQI consists of questions concerning patients' perception of the impact of skin diseases on different aspects of their health-related quality of life over the last week. This is not a scale. There are no minimum or maximum values. The quality index just captures a subjects perception of the impact of skin disease on different aspects of their health-related quality of life over the last week.
Time frame: Day 1 to Week 56
Change of Patient-Oriented Eczema Measure (POEM) from baseline at Week 4, 8, 12, 16, 24, 32, 40, 52 and 56
Change from baseline in Patient-Oriented Eczema Measure (POEM) at all scheduled visits. 7-item, patient-administered scale that assesses disease severity in children and adults. Subjects respond to questions about the frequency of 7 symptoms (itching, sleep disturbance, bleeding, weeping/oozing, cracking, flaking, and dryness/roughness) over the last week. Response categories include "No days," "1-2 days," "3-4 days," "5-6 days," and "Every day" with corresponding scores of 0, 1, 2, 3, and 4, respectively. Scores range from 0-28 with higher total scores indicating greater disease severity.
Time frame: Day 1 to Week 56
Ran from Apr 2021 to primary completion in Aug 2022, 15 months.
Of 150 industry-sponsored phase 3 interventional studies under Dermatitis, Atopic, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 28. This study's 15 months is below that.
Counting every sponsor, half of 157 studies reached it within 18 months; a quarter within 13 and three quarters within 28.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ivarmacitinib
Reistone Biopharma Company Limited →